Summary
Cannot assess alignment because no single AI-generated response text was provided for claim-by-claim verification against the supplied FDA label excerpts. Only general label excerpts were supplied (indication, dosing, warnings, interactions, and adverse reactions).
Category Scores
Accurate Statements
Tyvaso is the brand name for treprostinil.
Supported by provided label excerpt describing Tyvaso as a sterile formulation of treprostinil (Section 11 Description): 'Tyvaso is a sterile formulation of treprostinil...'.
Treprostinil is a prostacyclin analog used to treat pulmonary arterial hypertension.
Supported in part by Section 11 Description: 'treprostinil, a prostacyclin mimetic' and Section 1.1: Tyvaso indicated for PAH (WHO Group 1) to improve exercise ability.
Tyvaso (treprostinil inhalation) is used for pulmonary arterial hypertension (PAH).
Supported by Section 1.1: 'Tyvaso is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1)...'
Tyvaso is an inhaled therapy.
Supported by Section 2.1: 'intended for oral inhalation using the Tyvaso Inhalation System' and Section 11 Description: 'intended for administration by oral inhalation using the Tyvaso Inhalation System.'
Tyvaso is typically used multiple times per day.
Supported by Section 2.1: 'Tyvaso is dosed in 4 separate, equally spaced treatment sessions per day, during waking hours.'
Exact dosing schedules for Tyvaso depend on the prescriber’s plan and the specific device/formulation used.
Partially supported only by device/formulation language in Section 2.1 (Tyvaso intended for use with the Tyvaso Inhalation System). The excerpt provided does not address 'prescriber’s plan' variability.
Common side effects associated with inhaled treprostinil include bleeding risk.
Supported as 'Bleeding' under Warnings and Precautions (5.2) and listed as a potential adverse reaction (Section 6).
Serious risks can include bleeding risk.
Supported by Section 5.2: 'Tyvaso inhibits platelet aggregation and increases the risk of bleeding.' and Section 6: 'Bleeding.'
Serious risks can include low blood pressure effects.
Supported by Section 5.1: 'may produce symptomatic hypotension.' and Section 6: 'Decrease in systemic blood pressure.'
Low blood pressure effects may be more pronounced when Tyvaso is combined with other drugs that affect circulation.
Partially supported only in direction via 'Treprostinil is a pulmonary and systemic vasodilator' (Section 5.1) and the concept of drug-induced exposure changes in Section 5.3; however, the provided excerpts do not explicitly state 'more pronounced when combined with other drugs that affect circulation' specifically.
Unsupported Statements
In Australia, Tyvaso is known and prescribed as Tyvaso inhalation solution.
No Australian-market naming/availability statements are present in the supplied FDA label excerpts.
Tyvaso inhalation solution is an inhaled treprostinil formulation.
The provided excerpt describes Tyvaso as a sterile formulation intended for oral inhalation using the Tyvaso Inhalation System, but does not use the phrase 'Tyvaso inhalation solution' or explicitly equate that Australian term.
Tyvaso is a prescription medicine in many markets, including Australia.
No market-by-market prescription/availability statements are present in the supplied FDA label excerpts.
Tyvaso availability in Australia can depend on the specific formulation and local distribution arrangements.
No country-specific availability or distribution-arrangement statements are present in the supplied FDA label excerpts.
Tyvaso works by improving blood flow in the lungs.
The provided excerpts do not contain this mechanism statement.
Tyvaso works by reducing strain on the heart.
The provided excerpts do not contain this mechanism statement.
Common side effects associated with inhaled treprostinil include cough or throat irritation from inhalation.
The provided excerpted adverse reactions do not list cough or throat irritation.
Common side effects associated with inhaled treprostinil include headache.
The provided excerpted adverse reactions do not list headache.
Common side effects associated with inhaled treprostinil include dizziness.
The provided excerpted adverse reactions do not list dizziness.
Common side effects associated with inhaled treprostinil include flushing.
The provided excerpted adverse reactions do not list flushing.
Common side effects associated with inhaled treprostinil include nausea.
The provided excerpted adverse reactions do not list nausea.
Tyvaso is the brand name for treprostinil.
Not applicable (this statement is supported).
Contradictions
Low
AI Statement
Treprostinil is a prostacyclin analog used to treat pulmonary arterial hypertension.
Label Reference
No direct contradiction in supplied excerpts; 'prostacyclin mimetic' is used in label, not 'analog'. (No contradiction; naming difference).
Important Omissions
If evaluating full dosing accuracy, the AI claims did not include the specific details from Section 2.1 (4 equally spaced sessions per day during waking hours; each session 2 to 3 minutes; approximately 4 hours apart).
Importance:
Moderate
The AI claims about 'common side effects' list several specific symptoms (cough/throat irritation, headache, dizziness, flushing, nausea) which are not supported by the provided label excerpted adverse reactions (Section 6 only shows 'Decrease in systemic blood pressure' and 'Bleeding').
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most safety-related excerpts in the AI claims (bleeding risk, symptomatic hypotension) align with the supplied warnings/adverse reactions. However, multiple additional adverse event claims and country-specific availability statements are unsupported by the provided FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Several claims (mechanism statements, Australia-specific naming/availability, and specific 'common side effects' such as cough, headache, dizziness, flushing, nausea) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit claims to what is present in the provided label excerpts (PAH indication; dosing schedule details from Section 2.1; warnings for symptomatic hypotension and bleeding; drug interaction effects via CYP2C8 inhibitors/inducers; and adverse reactions explicitly listed). Remove or qualify unsupported Australia-specific and symptom lists unless corresponding label text is provided.